Emerging Clinician Scientist Awards – Application

Well-being, Health and Biomedical Discovery

Deadlines

Academic Unit: Inquire with unit

Memorial Deadline: Friday 26th, July 2019

External Deadline: Wednesday 31st, July 2019


Description

This program is made possible by a partnership between the Canadian Lung Association (CLA), CIHR-Institute of Circulatory and Respiratory Health (CIHR-ICRH) and AstraZeneca Canada (AZ Canada). The goal of the award is to support Emerging Clinician Scientists (e.g., Doctor of Medicine, Doctor of Medicine with graduate research training, Doctor of  Dental Sciences, PhD-Respiratory Therapist, PhD-Registered Nurse, PhD-Physiotherapist, PhD-Occupational Therapist) within the first five (5) years of their first faculty appointment in the establishment of their careers.

Research Areas

Priority areas include basic and translational research programs in chronic respiratory disease, including but not limited to chronic obstructive pulmonary disease, asthma, cough, chronic bronchitis, bronchiectasis, cystic fibrosis, Bronchopulmonary Dysplasia, Alpha-1 Antitrypsin Deficiency, Interstitial Lung Disease, and Idiopathic Pulmonary Fibrosis.

Funds Available

  • The total amount available for this funding opportunity is $400,000, enough to fund approximately 2 awards. The maximum amount per award is $100,000 per year for up to 2 years for a total of $200,000 per award.
  • These funds can only be used to support the research program of the clinician scientist. The funds cannot be allocated to the salary or benefits of the applicant.

Registration deadline: June 26, 2019
Application deadline: July 31, 2019

For more information, please consult the Canadian Lung Association Website.


Funding Sources

AstraZeneca Canada (AZ Canada)
Canadian Institute of Health Research (CIHR)
Canadian Lung Association (CLA)



This opportunity was posted by: RGCS

Last modified: May 16, 2019